Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18653132 | 1.00 | TP53 (0.33) | TP53NR1H2NR1H3LMNATSHR | |
| SCHEMBL18930401 | 0.95 | HCRTR1 (0.31) | TP53NR1H2NR1H3LMNATSHR | |
| SCHEMBL20643784 | 0.94 | ALOX5AP (0.32) | — | |
| SCHEMBL30554879 | 0.91 | TSHR (0.34) | TP53LMNATSHRHCRTR1HCRTR2 | |
| SCHEMBL12705318 | 0.91 | TSHR (0.34) | TP53LMNATSHRHCRTR1HCRTR2 | |
| SCHEMBL12016861 | 0.91 | TSHR (0.34) | TP53LMNATSHRHCRTR1HCRTR2 | |
| SCHEMBL30554881 | 0.91 | TSHR (0.34) | TP53LMNATSHRHCRTR1HCRTR2 | |
| SCHEMBL18925913 | 0.87 | LMNA (0.32) | TP53LMNATSHRHCRTR1HCRTR2 | |
| SCHEMBL18930400 | 0.87 | LMNA (0.32) | TP53LMNATSHRHCRTR1HCRTR2 | |
| SCHEMBL16404054 | 0.86 | ALOX5AP (0.31) | TP53LMNATSHRCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | TP53 996/4885NR1H2 257/4885NR1H3 185/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TP53 996/4885NR1H2 257/4885NR1H3 185/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | TP53 996/4885NR1H2 257/4885NR1H3 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.